Innoviva price target raised to $32 from $31 at Cantor Fitzgerald

Cantor Fitzgerald analyst Steve Seedhouse raised the firm’s price target on Innoviva (INVA) to $32 from $31 and keeps an Overweight rating on the shares. Q4 revenue of $114.6M exceeded expectations, driven by continued XacDuro inventory builds in China, potentially boosting royalties and milestones in 2026+, the analyst tells investors in a research note.